Hemolysis and hyperhomocysteinemia caused by cobalamin deficiency: three case reports and review of the literature

J Hematol Oncol. 2008 Dec 18:1:26. doi: 10.1186/1756-8722-1-26.

Abstract

Concurrent hemolysis in patients with vitamin B12 deficiency is a well-recognized phenomenon and has been attributed to intramedullary destruction of erythrocytes (ineffective erythropoiesis). Recent studies revealed that homocysteine increased the risk of hemolysis in vitamin B12 deficiency in vitro and there is a high frequency (30%) of vitamin B12 deficiency in asymptomatic patients with homozygous methylene tetrahydrofolate reductase (MTHFR) C677T mutation, a known cause of hyperhomocysteinemia. Here we report three patients with MTHFR mutations and vitamin B12 deficiency presenting with hemolytic anemia and severely elevated homocysteine levels. Patients demonstrated complete resolution of hemolysis with simultaneous normalization of serum homocysteine levels after vitamin B12 treatments. We reviewed pertinent literature, and hypothesized that hemolytic anemia may be more prevalent in patients who have a coexisting MTHFR gene mutation and vitamin B12 deficiency possibly related to severely elevated homocysteine levels. The hemolysis in these cases occurred predominantly in peripheral blood likely due to the combined effects of structurally defective erythrocytes and homocysteine-induced endothelial damage with microangiopathy.

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Anemia, Hemolytic / etiology*
  • Erythrocyte Transfusion
  • Female
  • Homocysteine / blood
  • Humans
  • Hyperhomocysteinemia / etiology*
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Middle Aged
  • Mutation*
  • Vitamin B 12 / therapeutic use
  • Vitamin B 12 Deficiency / complications*
  • Vitamin B 12 Deficiency / genetics
  • Vitamin B 12 Deficiency / therapy

Substances

  • Homocysteine
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Vitamin B 12